Table 1

Characteristics and outcomes of AIS patients treated with intravenous TPA

Characteristics and outcomesAIS patients treated with intravenous tPA
2020 (n=67)2019 (n=131)P value*
Age(y), mean±SD66.55±13.0166.76±13.040.914
Age, n (%)0.957
 8054 (80.6)106 (80.9)
 ≥8013 (19.4)25 (19.1)
Sex, n (%)0.457
 Male47 (70.1)85 (64.9)
 Female20 (29.9)46 (35.1)
Smoke history, n (%)0.083
 Yes20 (29.9)24 (18.3)
 No47 (70.1)103 (78.6)
 unknown0 (0.0)4 (3.1)
Alcohol history, n (%)0.924
 Yes14 (20.9)26 (19.9)
 No53 (79.1)102 (77.9)
 Uunknown0 (0.0)3 (2.3)
Comorbidities, n (%)
 Any49 (73.1)103 (78.6)0.286
 Cerebrovascular or cardiac disease21 (31.3)42 (32.1)0.835
 Hypertension41 (61.2)99 (75.6)0.022
 Diabetes mellitus17 (25.4)22 (16.8)0.175
Classification, No. (%)0.008
 CE, n (%)11 (16.4)14 (10.7)
 LAA, n (%)29 (43.3)42 (32.1)
 SAO, n (%)20 (29.9)58 (44.3)
 SUE, n (%)7 (10.4)2 (1.5)
 Other/unknown0 (0.0)15 (11.5)
Systolic-BP (mm Hg), mean±SD150.75±22.64147.14±190.266
Diastolic-BP (mm Hg), mean±SD85.19±12.3982.96±12.430.233
Blood glucose (mmol/L), mean±SD7.4±2.567.34±3.650.888
Laboratory Findings
 Cholesterol, mmol/L4.58±1.044.44±1.150.459
 Triglycerides, mmol/L1.51±0.651.83±1.520.065
 HDL-C, mmol/L1.17±0.361.21±0.50.557
 LDL-C, mmol/L2.91±0.942.68±0.870.134
 D-dimer, mg/L0.93±1.170.91±1.160.894
 INR1.04±0.081.04±0.10.845
 APTT, s30.99±7.932.72±7.670.155
 FIB, g/L3.15±0.753.41±0.990.047
 White cell count,×109/L7.61±2.167.32±2.560.416
 Platelet count,×109/L197.2±54.17201.57±60.630.613
Percentage of thrombolysis9.81%8.12%NA
DNT(min), mean±SD74.24±41.7146.36±21.59<0.001
ONT(min), mean±SD199.34±68.95155.12±62.46<0.001
NIHSS score
 Baseline NIHSS, mean±SD7.19±5.755.73±4.950.079
 Post-tPA NIHSS, mean±SD4.96±5.33.47±4.850.058
 1-day NIHSS, mean±SD4.52±5.183.49±4.930.188
 7-day NIHSS, mean±SD3.44±4.772.45±4.310.166
1-month mRS, mean±SD 1.75±2.061.04±1.680.010
1- month mRS, n (%) 0.020
 0–138 (56.7)97 (74.0)
 2–626 (38.8)33 (25.2)
 Unknown3 (4.5)1 (0.8)
Intracranial haemorrhage, n (%) 7 (10.5)2 (1.5)0.012
 1- month mortality, n (%)7 (10.5)6 (4.6)0.115
  • Data are presented as means±SD and No (%).

  • P values indicate differences between patients in epidemic period (2020) and non-epidemic period (2019).

  • p<0.05 was considered statistically significant.

  • 2 test (categorical variable) or t-test (continuous variable) calculation.

  • †Compared by linear regression adjusted on ONT.

  • AIS, acute ischaemic stroke; APTT, activated partial thromboplastin time; BP, blood pressure; CE, cardioembolic; DNT, door-to-needle time; FIB, fibrinogen; HDL-C, High-density lipoprotein cholesterol; INR, international normalised ratio; LAA, large artery atherosclerosis; LDL-C, Low density lipoprotein cholesterol; mRS, modified ranking scale; ; NIHSS, National Institute of Health Stroke Scale; ONT, onset-to-needle time; SAO, small-artery occlusion; SUE, stroke of undetermined aetiology; tPA, tissue plasminogen activator.